Cargando…
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
BACKGROUND: High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltrat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759258/ https://www.ncbi.nlm.nih.gov/pubmed/35026984 http://dx.doi.org/10.1186/s12864-021-08265-y |
_version_ | 1784633073780916224 |
---|---|
author | Liu, Ping Chen, Ruoxu Zhang, Xudong Fu, Ruiting Tao, Lin Jia, Wei |
author_facet | Liu, Ping Chen, Ruoxu Zhang, Xudong Fu, Ruiting Tao, Lin Jia, Wei |
author_sort | Liu, Ping |
collection | PubMed |
description | BACKGROUND: High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltration and immune checkpoints are highly correlated with immunotherapy. Here, we investigated immune cell infiltration and immune checkpoint values for prognosis and precise immunotherapy for high-grade serous ovarian carcinoma based on molecular subtype classification. RESULTS: “High antigen-presenting cells infiltration molecular subtype of high-grade serous ovarian carcinoma” was identified in immune cell infiltration profiles. Each of the three immune cell infiltration clusters (A, B, and C) demonstrated distinct immune cell characterization, with immune cell infiltration cluster C exhibiting high antigen-presenting cell infiltration, improved prognosis, and higher sensitivity to immunotherapy. Programmed death-1/programmed death ligand 1 has a prognostic and predictive role that can help classify molecular subtypes. CONCLUSIONS: Our findings redefined a unique molecular subtype of high-grade serous ovarian carcinoma, suggesting that high-grade serous ovarian carcinoma patients with higher antigen-presenting cell infiltration and programmed death-1/programmed death ligand 1 expression can benefit from precise immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-021-08265-y. |
format | Online Article Text |
id | pubmed-8759258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87592582022-01-18 Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma Liu, Ping Chen, Ruoxu Zhang, Xudong Fu, Ruiting Tao, Lin Jia, Wei BMC Genomics Research BACKGROUND: High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltration and immune checkpoints are highly correlated with immunotherapy. Here, we investigated immune cell infiltration and immune checkpoint values for prognosis and precise immunotherapy for high-grade serous ovarian carcinoma based on molecular subtype classification. RESULTS: “High antigen-presenting cells infiltration molecular subtype of high-grade serous ovarian carcinoma” was identified in immune cell infiltration profiles. Each of the three immune cell infiltration clusters (A, B, and C) demonstrated distinct immune cell characterization, with immune cell infiltration cluster C exhibiting high antigen-presenting cell infiltration, improved prognosis, and higher sensitivity to immunotherapy. Programmed death-1/programmed death ligand 1 has a prognostic and predictive role that can help classify molecular subtypes. CONCLUSIONS: Our findings redefined a unique molecular subtype of high-grade serous ovarian carcinoma, suggesting that high-grade serous ovarian carcinoma patients with higher antigen-presenting cell infiltration and programmed death-1/programmed death ligand 1 expression can benefit from precise immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-021-08265-y. BioMed Central 2022-01-13 /pmc/articles/PMC8759258/ /pubmed/35026984 http://dx.doi.org/10.1186/s12864-021-08265-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liu, Ping Chen, Ruoxu Zhang, Xudong Fu, Ruiting Tao, Lin Jia, Wei Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
title | Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
title_full | Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
title_fullStr | Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
title_full_unstemmed | Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
title_short | Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
title_sort | combined pd-1/pd-l1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759258/ https://www.ncbi.nlm.nih.gov/pubmed/35026984 http://dx.doi.org/10.1186/s12864-021-08265-y |
work_keys_str_mv | AT liuping combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma AT chenruoxu combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma AT zhangxudong combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma AT furuiting combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma AT taolin combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma AT jiawei combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma |